Reading Time: 3 minutes

Vancouver, British Columbia–(Newsfile Corp. – September 14, 2020) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark”) is pleased to announce that 2 of its most recent abstract submissions for the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition have resulted in invitations to submit full applications for funding. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of Health Research – Institute of Cancer Research, and Brain Canada Foundation, evaluated the abstracts for their relevance to funding opportunities in the prevention and early detection of cancer.

BioMark would like to thank Dr. David Wishart and his TMIC (The Metabolomics Innovation Centre) team for their abstract which focused on the use of a robust panel of biomarkers for potential early lung cancer screening. In addition, Dr. Horacio Bach’s (University of British Columbia) abstract relates to the development of an affordable enzyme-linked immunoassay (ELISA) kit which are commonly used in laboratories for clinical diagnosis. This customized ELISA kit has been developed using highly specific monoclonal antibodies and tested against industry gold standard Liquid-chromatography-tandem-mass-spectrometry (LC-MS/MS) for potential cancer screening application ideally suited for remote settings. “We have been working with both Drs. Wishart and Bach over the years and are delighted to be associated with them and look to support them to submit their full application due by mid October. We are excited to be part of this competitive application which seeks to support next generation of disruptive technologies in cancer,” says BioMark CEO, Rashid Bux.

About Sparks Grant

The Canadian Cancer Society (CCS), the Canadian Institutes of Health Research – Institute of Cancer Research (CIHR-ICR), and Brain Canada Foundation (BC or Brain Canada) have committed a total of up to $2.4M over one year to jointly fund Spark Grants focused on Novel Technology Applications in Cancer Prevention and Early Detection.

Background

The intent of the Novel Technology Application in Cancer Prevention and Early Detection program is to “spark” and accelerate new activity in the development and/or application of truly novel approaches to cancer prevention and early detection. To accelerate progress and uptake in cancer prevention and early detection in the short- to medium-term, CCS, CIHR-ICR and BC are launching this funding opportunity to support Spark Grants designed to gather pilot data to drive the application of truly innovative new technologies, or the novel repurposing of existing technologies into the study of cancer prevention and early detection.

Spark Grants will support preliminary research to establish proof of principle in novel cancer prevention and early detection approaches. The goal is to fund high risk, high reward studies, that provide sufficient rationale and/or preliminary data to convince reviewers of the novelty and feasibility of the proposed work. Spark Grants are intended to support the development of new partnerships and the exploration of highly novel concepts, involving researchers from any research area, and particularly from non-traditional cancer fields, such as engineering, AI, robotics, physics, nanoscience, statistics, informatics, computer and data sciences, behavioural science, and any other discipline poised to seed the next generation of disruptive technologies in cancer.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website https://thecse.com/.

For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved, or disapproved the content of this press release.

Powered by WPeMatico